EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effect of a combination of C. longa and B. serrata extracts on hand osteoarthritis. Results of a double-blind, randomized, placebo-controlled, multicenter trial

Yves Henrotin, Frédéric de Schrijver, Kurt De Vlam, Mieke Devinck, Rik Joos, Hilde Luyten, Quentin Rasmont, Marthe Van den Berghe, Tine Vanhaverbeke, Johan Vanhoof, Louis Van Praet, Ruth Wittoek

Osteoarthritis and Cartilage · 2025

DOI: 10.1016/j.joca.2025.06.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Osteoarthritis and Cartilage, 2025. Verfasst von Yves Henrotin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Service de kinésithérapie et réadaptation Fonctionnelle, Hôpital Princesse Paola, Vivalia Marche-en-Famenne, musculoSKeletal Innovative research Lab …. Hauptthemen laut MEDLINE: Osteoarthritis, Plant Extracts, Hand Joints, Phytotherapy. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tilman SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficacy and safety of a combination of patented C. longa and B. serrata extracts (CBTIL) in patients with hand osteoarthritis compared with placebo. DESIGN: This 3-month, multicentre, randomized, double-blind, placebo-controlled study enrolled patients with symptomatic hand osteoarthritis, with a body mass index ≤ 35 Kg/m2, and who met the American College of Rheumatology criteria for osteoarthritis of the hand (CUBO/NCT05570123). Participants received either two tablets of CBTIL or two placebo tablets per day. The primary endpoint was the difference in pain change on the visual analog scale between baseline and month 3. Secondary outcomes included the number of painful and swollen joints, functional score, quality of life, patient global assessment, grip strength, analgesic consumption, and treatment tolerance. RESULTS: 162 patients were randomly assigned to receive CBTIL (n=83) or placebo (n=79). In the Intention-to-treat analysis, the mean decrease (indicating pain relieve) from baseline to month 3 on the pain scale (primary endpoint) was -24.7 mm (95% Confidence Interval (CI) [-30.7 to -18.7]) in patient assigned to CBTIL group and -16.2 mm (95% CI [-22.5 to -9.9]) in patients assigned in placebo group (Difference between groups: -8.5 mm (95% CI [-16.4 to -0.6]; p = 0.03). At 3 months, the patient's global assessment (-9.6 mm [95% CI -16.9 to -2.2]), the percentage of patients achieving an acceptable symptom status (PASS) (Odd ratio (OR) 1.9 [95% CI 1.0 to 3.8]), Short Form-36 (SF-36) pain (7.1 units [95% CI 1.7 to 12.4]), and SF36 health change (6.7 units [95% CI 1.2 to 12.2]) were significantly improved by CBTIL compared to placebo. Other outcomes did not significantly differ between the two groups. No significant difference was observed regarding adverse events between the groups. CONCLUSIONS: CBTIL relieves pain in patients with hand osteoarthritis. Together with its safety, this clinically relevant symptomatic effect suggests that CBTIL may be an alternative to oral NSAIDs and analgesics for managing symptomatic hand osteoarthritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoarthritisPlant ExtractsHand JointsPhytotherapyHumansDouble-Blind MethodFemaleMaleMiddle AgedAgedPain MeasurementTreatment OutcomeQuality of LifeHand Strength

Stichwörter der Autor:innen

BoswelliaClinical trialCurcuminHandOsteoarthritis

Substanzen

Plant Extracts

Autor:innen und Institutionen

  • Service de kinésithérapie et réadaptation Fonctionnelle, Hôpital Princesse Paola, Vivalia Marche-en-Famenne, musculoSKeletal Innovative research Lab (mSKIL), Université de Liège, Liège, Belgium. Electronic address: yhen…
  • AZ Sint-Elisabeth Herentals, Herentals, Belgium. Electronic address: frederic.deschrijver@azherentals.be.
  • UZ Leuven, Leuven, Belgium. Electronic address: kurt.devlam@uzleuven.be.
  • AZ St Lucas, Brugge, Belgium. Electronic address: Mieke.Devinck@stlucas.be.
  • ZNA Jan Palfijn, Antwerp, Belgium. Electronic address: rik.joos@zna.be.
  • AZ St Lucas, Gand, Belgium. Electronic address: Hilde.Luyten@AZSTLUCAS.BE.

Förderung

  • Tilman SA

Zitieren

APA

Henrotin, Y., de Schrijver, F., De Vlam, K., Devinck, M., Joos, R., Luyten, H., Rasmont, Q., Van den Berghe, M., Vanhaverbeke, T., Vanhoof, J., Van Praet, L., & Wittoek, R. (2025). Effect of a combination of C. longa and B. serrata extracts on hand osteoarthritis. Results of a double-blind, randomized, placebo-controlled, multicenter trial. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2025.06.005

Vancouver

Henrotin Y, de Schrijver F, De Vlam K, Devinck M, Joos R, Luyten H, et al. Effect of a combination of C. longa and B. serrata extracts on hand osteoarthritis. Results of a double-blind, randomized, placebo-controlled, multicenter trial. Osteoarthritis and Cartilage. 2025. doi:10.1016/j.joca.2025.06.005

BibTeX
@article{Henrotin2025,
  author = {Henrotin, Yves and de Schrijver, Frédéric and De Vlam, Kurt and Devinck, Mieke and Joos, Rik and Luyten, Hilde and Rasmont, Quentin and Van den Berghe, Marthe and Vanhaverbeke, Tine and Vanhoof, Johan and Van Praet, Louis and Wittoek, Ruth},
  title = {Effect of a combination of C. longa and B. serrata extracts on hand osteoarthritis. Results of a double-blind, randomized, placebo-controlled, multicenter trial},
  journal = {Osteoarthritis and Cartilage},
  year = {2025},
  doi = {10.1016/j.joca.2025.06.005}
}
Kostenlos starten →